Bruce G. Redman, DO | Authors

Immunotherapy in Renal Cell Carcinoma

June 01, 1999

Very little has changed in the management of advanced renal cell carcinoma since the approval of interleukin-2 (IL-2, aldesleukin [Proleukin]) in 1992 by the FDA for the systemic treatment of this disease. Dr. Bukowski succinctly reviews the